Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1287

1.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Jan 21. doi: 10.1038/s41391-018-0124-z. [Epub ahead of print]

PMID:
30664734
2.

Characterisation and development of aspirin inducible biosensors in E. coli and SimCells.

Chen JX, Steel H, Wu YH, Wang Y, Xu J, Rampley CPN, Thompson IP, Papachristodoulou A, Huang WE.

Appl Environ Microbiol. 2019 Jan 18. pii: AEM.02959-18. doi: 10.1128/AEM.02959-18. [Epub ahead of print]

PMID:
30658983
3.

Structural thalamo-frontal hypoconnectivity is related to oculomotor corollary discharge dysfunction in schizophrenia.

Yao B, Neggers SFW, Rolfs M, Rösler L, Thompson IA, Hopman HJ, Ghermezi L, Kahn RS, Thakkar KN.

J Neurosci. 2019 Jan 10. pii: 1473-18. doi: 10.1523/JNEUROSCI.1473-18.2019. [Epub ahead of print]

PMID:
30630882
4.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Jan 8. doi: 10.1038/s41588-018-0330-6. [Epub ahead of print]

PMID:
30622367
5.

Using stable isotope fractionation factors to identify Cr(VI) reduction pathways: Metal-mineral-microbe interactions.

Zhang Q, Amor K, Galer SJG, Thompson I, Porcelli D.

Water Res. 2018 Dec 19;151:98-109. doi: 10.1016/j.watres.2018.11.088. [Epub ahead of print]

PMID:
30594094
6.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK.

J Clin Oncol. 2018 Dec 21:JCO1801279. doi: 10.1200/JCO.18.01279. [Epub ahead of print]

PMID:
30576268
7.

Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride.

Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM.

Cancer Prev Res (Phila). 2018 Dec 11. doi: 10.1158/1940-6207.CAPR-18-0284. [Epub ahead of print]

PMID:
30538099
8.

Primary Angiosarcoma of the Cervix: Case Report of a Rare Lesion.

Shah VI, Rowlands GL, Thompson IW, Sumathi VP, McCluggage WG.

Int J Gynecol Pathol. 2018 Dec 3. doi: 10.1097/PGP.0000000000000567. [Epub ahead of print]

PMID:
30516618
9.

Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy.

Thompson IA, Durrani AK, Patel S.

Eye (Lond). 2018 Dec 3. doi: 10.1038/s41433-018-0286-x. [Epub ahead of print]

PMID:
30510234
10.

Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies.

Eapen MS, Sharma P, Thompson IE, Lu W, Myers S, Hansbro PM, Sohal SS.

Lab Invest. 2018 Nov 19. doi: 10.1038/s41374-018-0146-0. [Epub ahead of print] Review.

PMID:
30451982
11.

Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.

Liss MA, Al-Bayati O, Gelfond J, Goros M, Ullevig S, DiGiovanni J, Hamilton-Reeves J, O'Keefe D, Bacich D, Weaver B, Leach R, Thompson IM.

Prostate Cancer Prostatic Dis. 2018 Nov 1. doi: 10.1038/s41391-018-0105-2. [Epub ahead of print]

PMID:
30385837
12.

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107.

Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P.

Kidney Cancer. 2017 Nov 27;1(2):123-132. doi: 10.3233/KCA-170018.

13.

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.

Hernandez J, Gelfond J, Goros M, Liss MA, Liang Y, Ankerst D, Thompson IM Jr, Leach RJ.

PLoS One. 2018 Oct 9;13(10):e0204823. doi: 10.1371/journal.pone.0204823. eCollection 2018.

14.

Role of Genetic Susceptibility in the Development of Bronchopulmonary Dysplasia.

Parad RB, Winston AB, Kalish LA, Gupta M, Thompson I, Sheldon Y, Morey J, Van Marter LJ.

J Pediatr. 2018 Dec;203:234-241.e2. doi: 10.1016/j.jpeds.2018.07.099. Epub 2018 Oct 1.

PMID:
30287068
15.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.

Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.

16.

FIVE-YEAR FUNCTIONAL OUTCOMES AFTER EPIRETINAL MEMBRANE SURGERY: A Prospective, Controlled Study.

Jonna G, Thompson IA, Mendel TA, Kim SJ.

Retina. 2018 Sep 17. doi: 10.1097/IAE.0000000000002323. [Epub ahead of print]

PMID:
30234853
17.

Experimental Evidence of a Variant Neutron Spectrum from the T(t,2n)α Reaction at Center-of-Mass Energies in the Range of 16-50 keV.

Gatu Johnson M, Forrest CJ, Sayre DB, Bacher A, Bourgade JL, Brune CR, Caggiano JA, Casey DT, Frenje JA, Glebov VY, Hale GM, Hatarik R, Herrmann HW, Janezic R, Kim YH, Knauer JP, Landoas O, McNabb DP, Paris MW, Petrasso RD, Pino JE, Quaglioni S, Rosse B, Sanchez J, Sangster TC, Sio H, Shmayda W, Stoeckl C, Thompson I, Zylstra AB.

Phys Rev Lett. 2018 Jul 27;121(4):042501. doi: 10.1103/PhysRevLett.121.042501.

PMID:
30095940
18.

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.

Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, Cohn BA, Cook MB, Flicker L, Freedman ND, Giles GG, Giovannucci E, Gislefoss RE, Hankey GJ, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luben RN, Luostarinen T, Männistö S, Metter EJ, Mikami K, Milne RL, Ozasa K, Platz EA, Quirós JR, Rissanen H, Sawada N, Stampfer M, Stanczyk FZ, Stattin P, Tamakoshi A, Tangen CM, Thompson IM, Tsilidis KK, Tsugane S, Ursin G, Vatten L, Weiss NS, Yeap BB, Allen NE, Key TJ, Travis RC.

Eur Urol. 2018 Nov;74(5):585-594. doi: 10.1016/j.eururo.2018.07.024. Epub 2018 Aug 1.

19.

mTOR inhibitors for treatment of low-risk prostate cancer.

Liss MA, Rickborn L, DiGiovanni J, Bacich D, DeGraffenried LA, Parihar M, Thompson IM, Sharp ZD.

Med Hypotheses. 2018 Aug;117:63-68. doi: 10.1016/j.mehy.2018.06.004. Epub 2018 Jun 5.

PMID:
30077200
20.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
21.

Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy.

McMillan HJ, Telegrafi A, Singleton A, Cho MT, Lelli D, Lynn FC, Griffin J, Asamoah A, Rinne T, Erasmus CE, Koolen DA, Haaxma CA, Keren B, Doummar D, Mignot C, Thompson I, Velsher L, Dehghani M, Vahidi Mehrjardi MY, Maroofian R, Tchan M, Simons C, Christodoulou J, Martín-Hernández E, Guillen Sacoto MJ, Henderson LB, McLaughlin H, Molday LL, Molday RS, Yoon G.

Orphanet J Rare Dis. 2018 May 31;13(1):86. doi: 10.1186/s13023-018-0825-3.

22.

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.

Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM.

Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6.

PMID:
29976469
23.

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL III, Vogelzang NJ, Thompson IM Jr, Moinpour CM.

J Patient Rep Outcomes. 2018 Jun 13;2:27. doi: 10.1186/s41687-018-0054-5. eCollection 2017.

24.

Woodland caribou habitat selection patterns in relation to predation risk and forage abundance depend on reproductive state.

Viejou R, Avgar T, Brown GS, Patterson BR, Reid DEB, Rodgers AR, Shuter J, Thompson ID, Fryxell JM.

Ecol Evol. 2018 May 4;8(11):5863-5872. doi: 10.1002/ece3.4124. eCollection 2018 Jun.

25.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Aug;55:117-122. doi: 10.1016/j.canep.2018.06.005. Epub 2018 Jun 21.

PMID:
29936140
26.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

27.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Jan 8;:.

PMID:
29892016
28.

Operationalizing and validating disciplinary literacy in secondary education.

Spires HA, Kerkhoff SN, Graham ACK, Thompson I, Lee JK.

Read Writ. 2018;31(6):1401-1434. doi: 10.1007/s11145-018-9839-4. Epub 2018 Mar 21.

29.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

PMID:
29801011
30.

The pendulum swings back: Screening for prostate cancer in 2018.

Thompson IM Jr.

Cancer. 2018 Jul 1;124(13):2690-2692. doi: 10.1002/cncr.31555. Epub 2018 May 22. No abstract available.

PMID:
29786846
31.

Raman-activated cell sorting and metagenomic sequencing revealing carbon-fixing bacteria in the ocean.

Jing X, Gou H, Gong Y, Su X, Xu, Ji Y, Song Y, Thompson IP, Xu J, Huang WE.

Environ Microbiol. 2018 May 4. doi: 10.1111/1462-2920.14268. [Epub ahead of print]

PMID:
29727057
32.

Identification of Smoking-Associated Differentially Methylated Regions Using Reduced Representation Bisulfite Sequencing and Cell type-Specific Enhancer Activation and Gene Expression.

Wan M, Bennett BD, Pittman GS, Campbell MR, Reynolds LM, Porter DK, Crowl CL, Wang X, Su D, Englert NA, Thompson IJ, Liu Y, Bell DA.

Environ Health Perspect. 2018 Apr 27;126(4):047015. doi: 10.1289/EHP2395.

33.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

PMID:
29624463
34.

Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

Thompson I Jr, Goodman P, Tangen C.

J Natl Cancer Inst. 2018 Nov 1;110(11):1159-1160. doi: 10.1093/jnci/djy038. No abstract available.

PMID:
29547919
35.

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.

Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr.

J Natl Cancer Inst. 2018 Nov 1;110(11):1208-1215. doi: 10.1093/jnci/djy035.

PMID:
29534197
36.

The exceptional value of intact forest ecosystems.

Watson JEM, Evans T, Venter O, Williams B, Tulloch A, Stewart C, Thompson I, Ray JC, Murray K, Salazar A, McAlpine C, Potapov P, Walston J, Robinson JG, Painter M, Wilkie D, Filardi C, Laurance WF, Houghton RA, Maxwell S, Grantham H, Samper C, Wang S, Laestadius L, Runting RK, Silva-Chávez GA, Ervin J, Lindenmayer D.

Nat Ecol Evol. 2018 Apr;2(4):599-610. doi: 10.1038/s41559-018-0490-x. Epub 2018 Feb 26. Review.

37.

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD.

Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.

38.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

PMID:
29433975
39.

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW.

Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9.

PMID:
29433973
40.

Nylon as an in vitro scaffold for three-dimensional study of neural cells.

Batth A, Thompson I.

J Biomed Mater Res A. 2018 Jun;106(6):1575-1584. doi: 10.1002/jbm.a.36367. Epub 2018 Feb 19.

PMID:
29430862
41.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2018 Feb 5. pii: S2405-4569(18)30011-7. doi: 10.1016/j.euf.2018.01.010. [Epub ahead of print]

PMID:
29422418
42.

Organizing a clinical trial for the new investigator.

Kukreja JB, Thompson IM Jr, Chapin BF.

Urol Oncol. 2018 Feb 1. pii: S1078-1439(17)30646-4. doi: 10.1016/j.urolonc.2017.12.017. [Epub ahead of print] Review.

PMID:
29395953
43.

Effect of the concentration of circulating prolactin on dairy cows' responsiveness to domperidone injection.

Tong JJ, Thompson IM, Zhao X, Lacasse P.

J Dairy Sci. 2018 Mar;101(3):2579-2587. doi: 10.3168/jds.2017-13828. Epub 2018 Jan 10.

PMID:
29331457
44.

Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.

Chu LW, Till C, Yang B, Tangen CM, Goodman PJ, Yu K, Zhu Y, Han S, Hoque AM, Ambrosone C, Thompson I, Leach R, Hsing AW.

Mol Carcinog. 2018 Mar;57(3):462-466. doi: 10.1002/mc.22770. Epub 2018 Jan 12.

PMID:
29318656
45.

Chemoprevention in Prostate Cancer: Current Perspective and Future Directions.

Rivero JR Jr, Thompson IM Jr, Liss MA, Kaushik D.

Cold Spring Harb Perspect Med. 2018 Oct 1;8(10). pii: a030494. doi: 10.1101/cshperspect.a030494. Review.

PMID:
29311128
46.

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.

Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA, Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA, Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E, Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ, Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM, Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC.

PLoS One. 2017 Dec 27;12(12):e0187741. doi: 10.1371/journal.pone.0187741. eCollection 2017.

47.

Effect of 17β-estradiol on milk production, hormone secretion, and mammary gland gene expression in dairy cows.

Tong JJ, Thompson IM, Zhao X, Lacasse P.

J Dairy Sci. 2018 Mar;101(3):2588-2601. doi: 10.3168/jds.2017-13353. Epub 2017 Dec 21.

PMID:
29274969
48.

Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins.

Shi T, Quek SI, Gao Y, Nicora CD, Nie S, Fillmore TL, Liu T, Rodland KD, Smith RD, Leach RJ, Thompson IM, Vitello EA, Ellis WJ, Liu AY, Qian WJ.

Oncotarget. 2017 Oct 9;8(60):101887-101898. doi: 10.18632/oncotarget.21710. eCollection 2017 Nov 24.

49.

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.

PMID:
29228205
50.

Raman-Deuterium Isotope Probing for in-situ identification of antimicrobial resistant bacteria in Thames River.

Song Y, Cui L, López JÁS, Xu J, Zhu YG, Thompson IP, Huang WE.

Sci Rep. 2017 Nov 30;7(1):16648. doi: 10.1038/s41598-017-16898-x.

Supplemental Content

Loading ...
Support Center